Future of GPR109A agonists in the treatment of dyslipidaemia

@article{Wanders2011FutureOG,
  title={Future of GPR109A agonists in the treatment of dyslipidaemia},
  author={D. Wanders and R. Judd},
  journal={Diabetes},
  year={2011},
  volume={13}
}
Abnormal blood lipids are the major modifiable risk factor underlying the development of cardiovascular disease. Niacin has a profound ability to reduce low‐density lipoprotein‐C, very low‐density lipoprotein‐C and triglycerides and is the most effective pharmacological agent to increase high‐density lipoprotein‐C. Recently, the receptor for niacin, GPR109A, was discovered. GPR109A in the adipocyte mediates a niacin‐induced inhibition of lipolysis, which could play a crucial part in its role as… Expand
Niacin: The Evidence, Clinical Use, and Future Directions
TLDR
The widespread use of niacin to treat residual lipid abnormalities such as low HDL cholesterol, when used in combination with statins among patients achieving very low (<75 mg/dL) low-density lipoprotein cholesterol levels, is currently not supported by clinical outcome trials. Expand
Loss of GPR109A/HCAR2 induces aging-associated hepatic steatosis
TLDR
Results indicate that during aging, GPR109A modulates de novo lipid accumulation in liver and adipose tissue, and its dysregulation can lead to age-associated obesity and hepatic steatosis. Expand
3,5-Dihydroxybenzoic Acid, a Specific Agonist for Hydroxycarboxylic Acid 1, Inhibits Lipolysis in Adipocytes
TLDR
3-hydroxybenzoic acid (3-HBA) is shown to be a useful tool for the in vivo study of HCA1 function and offers a base for further HCA2 agonist design, whereas 3,5-dihydroxybenzosic acid is a specific agonist for only H CA1 (EC50 ∼150 μM). Expand
NIACIN AND NIACIN / LAROPIPRANT COMBINATION: OPENING NEW HOPES FOR DYSLIPIDEMIA AND CARDIOVASCULAR DISEASES WITH FEW NOVEL ACTIONS
TLDR
Novel actions of niacin in immune system improves peripheral mononuclear cells cell viability, decrease in genotoxic stress, drug for hyperphosphatemia, improvement in symptoms of Parkinsonism and psoriasis, and the combination of ERN and Laropiprant in reducing overall risk of cardiovascular diseases is discussed in detail. Expand
GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice
TLDR
Hippuric acid (HA), which is a diet-derived phenolic acid, inhibits bone resorption and increases bone mass in wild type mice, but not in G-protein coupled receptor (GPR109A) knockout mice, which suggests that GPR 109A mediates the effects of HA on inhibiting bone resOrption during skeletal development. Expand
Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice.
TLDR
Niacin decreases hepatic CETP expression and plasma CETP mass by attenuated liver inflammation and macrophage content in response to its primary lipid-lowering effect, rather than by attenuating the macrophages CETPexpression level. Expand
Effects of pyrazole partial agonists on HCA2‐mediated flushing and VLDL‐triglyceride levels in mice
TLDR
Two partial agonists for HCA2, LUF 6281 and LUF6283 are evaluated with respect to their anti‐dyslipidaemic potential and cutaneous flushing effect. Expand
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
TLDR
The importance of understanding the role of GPCR receptors in the disease pathology, and their basic pharmacology, will pave the way to the development of novel pharmacological probes that will enable these targets to fulfill their promise for the treatment of these metabolic disorders. Expand
Molecular Insights of Diabetic Complications and Future Targets for Therapy
In Diabetes, hyperglycemia, insulin resistance, oxidative stress and inflammation are the known associates for the loss of β cell function. Indeed, number other factors influencing many otherExpand
Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome
TLDR
Exercise and niacin works synergistically to increase PON1 activity and concentration with little or no changes in lipoproteins or markers of lipid oxidation. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 72 REFERENCES
Niacin stimulates adiponectin secretion through the GPR109A receptor.
TLDR
Results demonstrate that the GPR109A receptor plays an important role in the dual regulation of adiponectin secretion and lipolysis. Expand
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
TLDR
Recent progress in understanding the physiological and pharmacological role of the nicotinic acid receptor is summarized and its potential use as a new target for the development of antidyslipidemic drugs to prevent and treat cardiovascular diseases is discussed. Expand
Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
TLDR
The data support the concept that the HDL-C lowering effect of niacin in wild-type mice is mediated through stimulation of GPR109A in hepatocytes, which leads to reduced hepatocyte ABCA1 expression and activity, decreased cholesterol efflux to nascent apoA-I, and reduced LDL-C levels. Expand
Mechanism of action of niacin.
TLDR
Initial data suggest that niacin, by inhibiting the hepatocyte surface expression of beta-chain adenosine triphosphate synthase (a recently reported HDL-apo A-I holoparticle receptor), inhibits the removal of HDL-AP-I. Expand
The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
TLDR
These findings provide evidence that GPR109A is a target for the drug Fumaderm and suggest that niacin should be investigated to treat psoriasis in addition to its role in treating lipid disorders. Expand
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
TLDR
It is found that in a mouse model of atherosclerosis, nicotinic acid inhibited disease progression under conditions that left total cholesterol and HDL cholesterol plasma levels unaffected and GPR109A mediates antiinflammatory effects, which may be useful for treating Atherosclerosis and other diseases. Expand
Novel patent publications on high-affinity nicotinic acid receptor agonists
TLDR
Highly potent GPR109A agonists with minimal flushing effects and robust free fatty acid reduction have been identified and will be critical to validate the therapeutic utility of this receptor. Expand
GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
TLDR
The data clearly indicate that GPR109A mediates nicotinic acid-induced flushing and that this effect involves release of PGE(2) and PGD(2), most likely from immune cells of the skin. Expand
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
TLDR
It is shown that the orphan G-protein-coupled receptor, 'protein upregulated in macrophages by interferon-γ' (mouse PUMA-G, human HM74), is highly expressed in adipose tissue and is a nicotinic acid receptor. Expand
Nicotinic acid: recent developments
TLDR
Recent developments suggest that the niacin receptor GPR109A is involved in flushing, but it does not explain multiple actions of niacIn, and actions ofniacin on diacylglycerolacyl transferase 2, ATP synthase β chain, and redox state may explain the multiple actions. Expand
...
1
2
3
4
5
...